Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | APLT |
---|---|---|
09:32 ET | 7444 | 4.615 |
09:36 ET | 1700 | 4.65 |
09:38 ET | 711 | 4.61 |
09:39 ET | 200 | 4.61 |
09:41 ET | 1900 | 4.6 |
09:43 ET | 200 | 4.59 |
09:45 ET | 1361 | 4.64 |
09:48 ET | 1814 | 4.61 |
09:50 ET | 2300 | 4.58 |
09:54 ET | 756 | 4.54 |
09:56 ET | 1500 | 4.55 |
09:57 ET | 300 | 4.56 |
09:59 ET | 1241 | 4.5101 |
10:01 ET | 1415 | 4.49 |
10:03 ET | 1307 | 4.51 |
10:06 ET | 514 | 4.51 |
10:08 ET | 1178 | 4.47 |
10:10 ET | 1312 | 4.525 |
10:12 ET | 1239 | 4.5 |
10:14 ET | 600 | 4.51 |
10:15 ET | 100 | 4.51 |
10:17 ET | 507 | 4.535 |
10:19 ET | 849 | 4.57 |
10:21 ET | 1718 | 4.55 |
10:24 ET | 913 | 4.54 |
10:26 ET | 3997 | 4.54 |
10:28 ET | 3663 | 4.55 |
10:30 ET | 538 | 4.54 |
10:32 ET | 2203 | 4.52 |
10:33 ET | 3412 | 4.53 |
10:35 ET | 2454 | 4.51 |
10:37 ET | 3086 | 4.49 |
10:39 ET | 3440 | 4.5 |
10:42 ET | 1200 | 4.505 |
10:44 ET | 1540 | 4.47 |
10:46 ET | 300 | 4.48 |
10:48 ET | 700 | 4.49 |
10:50 ET | 1200 | 4.505 |
10:51 ET | 15155 | 4.54 |
10:53 ET | 4917 | 4.53 |
10:55 ET | 870 | 4.53 |
10:57 ET | 3631 | 4.51 |
11:00 ET | 935 | 4.515 |
11:02 ET | 2110 | 4.505 |
11:04 ET | 1302 | 4.5 |
11:06 ET | 434 | 4.51 |
11:08 ET | 2399 | 4.51 |
11:09 ET | 600 | 4.5 |
11:11 ET | 1893 | 4.52 |
11:13 ET | 254 | 4.51 |
11:15 ET | 800 | 4.52 |
11:18 ET | 2850 | 4.51 |
11:20 ET | 402 | 4.51 |
11:22 ET | 6723 | 4.51 |
11:24 ET | 1000 | 4.52 |
11:26 ET | 2440 | 4.53 |
11:27 ET | 800 | 4.54 |
11:29 ET | 6115 | 4.55 |
11:31 ET | 1200 | 4.54 |
11:33 ET | 9068 | 4.57 |
11:36 ET | 897 | 4.55 |
11:38 ET | 4351 | 4.56 |
11:40 ET | 984 | 4.55 |
11:42 ET | 2024 | 4.575 |
11:44 ET | 3259 | 4.56 |
11:45 ET | 1600 | 4.56 |
11:47 ET | 2815 | 4.575 |
11:49 ET | 1796 | 4.58 |
11:51 ET | 500 | 4.585 |
11:54 ET | 3452 | 4.6 |
11:56 ET | 1920 | 4.625 |
11:58 ET | 5335 | 4.624 |
12:00 ET | 562 | 4.625 |
12:02 ET | 468 | 4.625 |
12:03 ET | 1890 | 4.64 |
12:05 ET | 1500 | 4.64 |
12:07 ET | 1400 | 4.645 |
12:09 ET | 2276 | 4.635 |
12:12 ET | 1270 | 4.62 |
12:14 ET | 4978 | 4.6 |
12:16 ET | 200 | 4.59 |
12:18 ET | 567 | 4.59 |
12:20 ET | 1200 | 4.6 |
12:21 ET | 800 | 4.6 |
12:23 ET | 4035 | 4.62 |
12:25 ET | 1358 | 4.64 |
12:27 ET | 1200 | 4.64 |
12:30 ET | 2925 | 4.66 |
12:32 ET | 1760 | 4.65 |
12:34 ET | 12500 | 4.675 |
12:38 ET | 2546 | 4.7 |
12:39 ET | 9879 | 4.69 |
12:41 ET | 200 | 4.68 |
12:43 ET | 3249 | 4.68 |
12:45 ET | 800 | 4.685 |
12:48 ET | 9619 | 4.675 |
12:50 ET | 5083 | 4.67 |
12:52 ET | 500 | 4.67 |
12:54 ET | 4519 | 4.675 |
12:56 ET | 1512 | 4.69 |
12:57 ET | 700 | 4.695 |
12:59 ET | 5495 | 4.7 |
01:01 ET | 4520 | 4.69 |
01:03 ET | 1352 | 4.7 |
01:06 ET | 4882 | 4.71 |
01:08 ET | 2225 | 4.7299 |
01:10 ET | 500 | 4.725 |
01:12 ET | 20504 | 4.7 |
01:14 ET | 6504 | 4.695 |
01:15 ET | 4200 | 4.675 |
01:17 ET | 18076 | 4.7 |
01:19 ET | 9819 | 4.7 |
01:21 ET | 9727 | 4.63 |
01:24 ET | 1863 | 4.62 |
01:26 ET | 1764 | 4.62 |
01:28 ET | 2406 | 4.625 |
01:30 ET | 5947 | 4.609 |
01:32 ET | 1200 | 4.605 |
01:33 ET | 4712 | 4.605 |
01:35 ET | 3356 | 4.61 |
01:37 ET | 4919 | 4.6 |
01:39 ET | 6760 | 4.62 |
01:42 ET | 1400 | 4.6 |
01:44 ET | 1640 | 4.61 |
01:46 ET | 400 | 4.61 |
01:48 ET | 2001 | 4.61 |
01:50 ET | 806 | 4.61 |
01:51 ET | 2210 | 4.615 |
01:53 ET | 3511 | 4.61 |
01:55 ET | 767 | 4.61 |
01:57 ET | 1500 | 4.615 |
02:00 ET | 2146 | 4.615 |
02:02 ET | 1133 | 4.615 |
02:04 ET | 2020 | 4.61 |
02:06 ET | 4278 | 4.605 |
02:08 ET | 1544 | 4.605 |
02:09 ET | 8662 | 4.63 |
02:11 ET | 2608 | 4.65 |
02:13 ET | 1843 | 4.64 |
02:15 ET | 1559 | 4.65 |
02:18 ET | 2447 | 4.68 |
02:20 ET | 1400 | 4.68 |
02:22 ET | 2200 | 4.68 |
02:24 ET | 32086 | 4.68 |
02:26 ET | 600 | 4.68 |
02:27 ET | 7114 | 4.62 |
02:29 ET | 5029 | 4.61 |
02:31 ET | 406 | 4.62 |
02:33 ET | 800 | 4.61 |
02:36 ET | 1824 | 4.62 |
02:38 ET | 1493 | 4.62 |
02:40 ET | 3286 | 4.62 |
02:42 ET | 5306 | 4.63 |
02:44 ET | 1909 | 4.63 |
02:45 ET | 3168 | 4.625 |
02:47 ET | 1452 | 4.625 |
02:49 ET | 3271 | 4.62 |
02:51 ET | 401 | 4.62 |
02:54 ET | 1100 | 4.63 |
02:56 ET | 400 | 4.62 |
02:58 ET | 1781 | 4.62 |
03:00 ET | 1475 | 4.64 |
03:02 ET | 2535 | 4.625 |
03:03 ET | 4578 | 4.6 |
03:05 ET | 615 | 4.59 |
03:07 ET | 3176 | 4.61 |
03:09 ET | 400 | 4.62 |
03:12 ET | 600 | 4.62 |
03:14 ET | 1592 | 4.61 |
03:16 ET | 2308 | 4.62 |
03:18 ET | 1125 | 4.61 |
03:20 ET | 6649 | 4.61 |
03:21 ET | 1347 | 4.6 |
03:23 ET | 400 | 4.605 |
03:25 ET | 4109 | 4.615 |
03:27 ET | 1377 | 4.615 |
03:30 ET | 5928 | 4.615 |
03:32 ET | 4587 | 4.615 |
03:34 ET | 1135 | 4.62 |
03:36 ET | 900 | 4.63 |
03:38 ET | 7003 | 4.625 |
03:39 ET | 4834 | 4.62 |
03:41 ET | 1400 | 4.63 |
03:43 ET | 6519 | 4.63 |
03:45 ET | 3241 | 4.65 |
03:48 ET | 7937 | 4.65 |
03:50 ET | 4527 | 4.65 |
03:52 ET | 60650 | 4.71 |
03:54 ET | 29896 | 4.72 |
03:56 ET | 75435 | 4.63 |
03:57 ET | 46361 | 4.615 |
03:59 ET | 33407 | 4.67 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Applied Therapeutics Inc | 533.6M | -2.4x | --- |
Iteos Therapeutics Inc | 536.1M | -3.9x | --- |
PureTech Health PLC | 553.5M | -10.6x | --- |
Third Harmonic Bio Inc | 532.3M | -17.4x | --- |
Northwest Biotherapeutics Inc | 516.8M | -6.8x | --- |
Lexeo Therapeutics Inc | 528.4M | -5.9x | --- |
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $533.6M |
---|---|
Revenue (TTM) | $-477.0K |
Shares Outstanding | 114.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.99 |
EPS | $-1.91 |
Book Value | $-0.20 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.